Those suffering from chronic obstructive pulmonary disease (COPD) often complain that exercise is too exhausting and leaves them breathless.

Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that concomitant therapy of chronic obstructive pulmonary disease with Perforomist™ Inhalation Solution (formoterol fumarate inhalation solution; FFIS), delivered by nebulization, and Spiriva® (tiotropium; TIO) is significantly more effective than treatment with tiotropium alone.

Patients with chronic obstructive pulmonary disease (COPD) who are in their final years of survival do not get the same benefits from pulmonary rehabilitation (PR) as patients who have more years left to live—regardless of their age, complicating illnesses or lung function, according to new research funded by the Veteran’s Administration, which will be presented at the American Thoracic Society’s 2008 International Conference in Toronto on Tuesday, May 20.